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A B S T R A C T
Severe malaria is a life-threatening condition caused by Plasmodium falciparum. Rupture of red blood
cells when merozoites release to the bloodstream is responsible for the clinical manifestations, febrile
fever reaching 39 8C, and other unspeciﬁc symptoms. P. falciparum is considered as the worst form of
malaria. Moreover, this species has cytoadherence to red blood cells. This can lead to an organic
dysfunction. People coming from hyper endemic areas have developed a partial immunity, but
immunodepressed people are a group with a greater risk. Due to the high mortality rate associated to
this disease, early diagnosis and a prompt treatment implementation are essential. However, the missed
or delayed diagnosis is one of the major reasons of reaching a severe malaria disease. This case reﬂects
the complexity of the diagnosis in an immigrant and immunodepressed patient with a haematological
neoplasm with a severe infection by P. falciparum due to the unspeciﬁed symptoms and the overlapping
of the same.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Malaria is a serious infectious disease caused by a parasite of the
Plasmodium spp.
The clinical manifestations of malaria differ with the geographic
distribution, Plasmodium species, epidemiology, age and immuni-
ty. In areas where malaria is hyper endemic, youngers and adults
may develop a partial immunity after repeated contact with the
parasite, and they are at relatively low risk of severe disease [1].
The incubation period varies between 12 and 15 days, whereas
individuals are asymptomatic, but on patients with partial
immunity this period can increase up to 30 days after returning
from the malaria endemic area [2].
The initial symptoms of malaria are nonspeciﬁc [1,2], and may
include fever, tachycardia, tachypnea, chills, anaemia, myalgia,
malaise, and other unspeciﬁc symptoms, secondary to the red
blood cells (RBC) lysis and the release of pro-inﬂammatory
cytokines to the bloodstream.
Plasmodium falciparum is responsible for the most severe form
of malaria. Cytoadherence of P. falciparum infected-RBC to the
endothellium of microvessels is thought to be the key mechanism
involved in pathogenesis of severe malaria. Cytoadherence leads to
microvascular sequestration of parasitized erythocytes in different
vital organs, developing partial blood ﬂow obstruction, endothelial* Corresponding author. Tel.: +34 916247265.
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4.0/).barrier breakdown and ﬁnally multiorgan failure and death
[3,4]. Increasing parasitemia is associated with increasing disease
severity. The World Health Organization (WHO) establishes a
cutoff of 5 percent of parazited-RBCs in low transmission areas,
and 10 percent in hyper endemic areas to deﬁne hyperparasitemia
for the diagnosis of severe malaria [1]. Semi-immune patients may
have substantial parasitemia with no clinical manifestations.
Nevertheless, individuals with higher risk of complicated malaria
include young children, nonimmune patients, pregnant women,
and immunocompromised patients [1].
Due to the high mortality rate associated to this disease, up to
15–20 percent [1] in complicated cases, early diagnosis and a
prompt treatment implementation are essential. The main
problem lies in countries with a low prevalence of malaria, where
the lack of clinic suspicion due to the unspeciﬁc symptoms can
delay the diagnosis and treatment.
The next description is a case of a patient with a haematological
neoplasm and associated immunodepression who was diagnosed
with a severe infection by P. falciparum. It reﬂects the complexity of
the diagnosis due to the unspeciﬁc and overlapped symptoms with
the patient’s leukaemia, reﬂecting the importance of a prompt
initiating highly active treatment in a very severe immunode-
pressed patient.
Case report
A 38-year-old Nigerian woman, living in Spain 7 years, went
back to Nigeria. In Nigeria, she attended to a regional hospitale under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Fig. 1. Haemoglobin levels and temperature evolution.
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an acute lymph proliferative syndrome. In addition, the patient had
severe anaemia; therefore, she needed blood transfusions (BT).
Due to the severity of the signs and symptoms (fatigue for 3–5
months, weight loss, analgesic non-responsive headache and
lumbar pain), the patient decided to return to a Spanish Emergency
Department. The patient was admitted at hospital for further
study. After obtaining a marrow biopsy and cytogenetic studies,
the patient was diagnosed with Myeloid Chronic Leukaemia (MCL)
bcr/abl positive in novo blast crisis and she started a quimiother-
apy treatment with a suitable response.
Coincidently with the severe aplasic phase, the patient was
febrile (39 8C) and had severe low RBC counts which required BT. In
the ﬁrst place these symptoms were associated with febrile
neutropenia and tumoral lysis syndrome. Despite the antimicro-
bial and antifungal wide spectrum treatment, it was detected lack
of response and all blood and urine test were negative. In addition,
the patient suffered severe undernourishment, mucositis and
mainly nocturnal anxiety, confusion, agitation and disorientation
episodes which required tranquilizers and sedative treatment.
Ten days after the hospital admission, the patient suffered a
sudden loss on conciousness which was, in ﬁrst place, associated
with the sedatives. Due to an acute respiratory distress syndrome
with tachycardia, dysnea, taquipnea, hipoxemia and respiratory
distress, the patient required endotracheal intubation and
mechanic ventilation in the Intensive Care Unit (ICU). Cardiovas-
cular dysfunction, renal failure and hepatomegaly were also
presented. During the ﬁrst 24 h the patient also suffered a
generalized tonic clonic seizure with horizontal nistagmus to
the left. Despite all the above signs, neuroimaging was normal. The
study of the cerebrospinal ﬂuid (CSF) showed a slight increase in
glucose (87 mg/dL), proteins (47 mg/dL) and cells (27 cells/M).
Because a leukemic inﬁltration was suspected regarding the
patients basal disease, an intrathecal triple chemotherapy (ITC)
was initiated. Subsequent CSF showed no blastic cells and ITC was
discontinued.
After 1 month a routine blood frotis was performed and parasite
P. falciparum forms were observed, and a 10 percent of parasitemia
was detected. With these ﬁndings the Pharmacy Department was
consulted for a recommended antimalarial treatment. Due to the
high parasitemia percentage, the organic dysfunction, the severe
immunodeﬁciency, the probable cloroquin resistance related to
the geographic origin of the infection and the oral intolerance
related with the mucositis, intravenous artesunate treatment was
initiated (2.4 mg/kg  3 initial dosing every 12 h, completed with
2.4 mg/kg every 24 h until the 4th day of treatment).
After 24 h from the beginning of the treatment, the parasitic
forms were almost eradicated with a major clinical improvement.
The antimalarial treatment was completed with an oral combina-
tion of atovaquone and proguanil for 3 days which eradicated the
infection completely. A close monitoring for artesunate haemolysis
for 4 weeks after treatment was recommended [2].
Finally the patient was discharged on the 29th day of the
chemotherapy treatment with an increase in neutrophils count
and the disappearance of the mucositis and the neurologic
manifestations.
Discussion
We have faced a severe case of malaria produced by P.
falciparum with a high parasitemia in a context of severe
immunodeﬁciency due to the myelosuppressor chemotherapy
treatment. Additionally, the patient comes from an endemic area
of malaria which provides a partial immunity against the parasite
as a protective factor [1,2].Regarding malaria transmission, although the mosquito
bite is the main course of transmission, there are cases of
vertical transmission, through BT and organ transplants
[1,2]. The malaria transmission through BT from asymptomatic
carriers is a major problem in tropical Africa (the patient
received BT in a country where safety and quality controls are
uncertain).
Regarding the symptoms, the patient suffered febrile peaks
reaching 39 8C which were impossible to relate to a focus of
infection. Moreover, the patient suffered a systemic dysfunction
involving the main organs affected by the cytoadherence of
P. falciparum [3]. In the course of malaria, a regular fever pattern
is not always present, especially the falciparum malaria [2].
Nevertheless there was a clear overlapping between the febrile
peaks and the acute haemoglobin reduction which could be related
to the RBC cells when merozoites escape to the bloodstream
(Fig. 1).
Cerebral malaria should be considered in anyone with impaired
consciousness who have recently travelled in a endemic area,
especially people with no neurologic focus and with normal CSF
[5]. The main risk factors for cerebral malaria are: age,
undernourishment, high parasitemia and immunosuppression
[5]; most of these risk factors were present in our patient, in
addition, her cerebral manifestations could not be associated with
tumoral inﬁltration.
One of the main aspects of this case was the lack of suspicion
and the delay on the diagnosis due to the overlapping between
malaria and basal leukaemia symptoms. The diagnosis was
achieved by a routine blood control test a month after hospital
admission. This delay was possibly explained by the fact that the
patient received several blood transfusions which could have
cleared the parasitemia.
High effective treatment that could reduce the parasitemia as
fast as possible was totally necessary. This treatment consisted in
the administration of intravenous anti-malaria drugs; at present,
there are two alternatives: quinine gluconate associated with
tetracyclines/clindamicin or artesunate [6]. Artesunate was the
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favourable risk/beneﬁt proﬁle and effectiveness than quinine
when treating patients with high parasitemia [7]. The superiority
of artesunate is probably associated to its unique mechanism
with an antiparasite activity based on the removal of immature
trophozoites in the blood stream (ring-shaped), reducing the
parasitemia quickly and preventing cytoadherence, which is
the main physiopathologic mechanism of severe malaria due to
P. falciparum [8]. The treatment was completed with oral
administration of the combination of atovaquone with proguanil
according to the North American Institute for Public Health and
the Centers for Disease Control and Prevention (CDC) [9]. Another
possibility, as recommended by the WHO, could be oral
artemisinines [1]. The atovaquone and proguanil coformulation
was chosen due to its excellent tolerance with a simple dosage
and the clinical experience.
We concluded that it is mandatory to consider malaria in all
febrile patients coming from endemic areas (imported malaria) [2],
regardless of other comorbidities. Rapid diagnostic tests for
malaria such as Test BinaxNOW [10] Malaria allow accurate
diagnosis and prompt and effective treatment [11].
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